Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Research And Development Expenses	$ 3,600,000.0	$ 3,900,000.0
Cash And Cash Equivalent	23,732,379	$ 33,061,711	$ 20,581,313	$ 19,444,737
Deferred Revenue	10,000,000		12,512
Accounts Receivable	$ 72,371		$ 12,510
Warrants And Options [Member]
Potentially Dilutive Securities Excluded From The Computation Of Eps	6,346,268
Money Market Funds [Member]
Cash And Cash Equivalent	$ 10,200,000.0